Joint Venture

Angle PLC
22 September 2004


For Immediate Release                                          22 September 2004


                                   ANGLE plc

                      DEVELOPMENT OF HEART HEALTHY DRINK

            PROVEXIS ANNOUNCES JOINT VENTURE WITH NUTRINNOVATOR


ANGLE plc, ('ANGLE'), is pleased to announce that venture Company, Provexis
Limited has agreed a joint venture with Nutrinnovator Holdings plc to develop a
new heart-healthy drink.

The drink will be the first of its kind; a juice drink containing a patented
natural fruit extract which has been proven in human trials to 'thin' the blood
and benefit the circulation. Provexis collaborated with the Rowett Institute (a
leading human nutrition research centre) over a four year period to develop and
clinically test a patented ingredient called CardioFlow(R).

CardioFlow(R) works by reducing the 'stickiness' of blood platelets which
prevents them from self-aggregating and potentially initiating a fatal internal
blood clot called a thrombus. The natural fruit-derived extract is proven to
provide real health benefits without affecting the taste, and without the
side-effects typically associated with aspirin. The joint venture partners
believe that the product will exploit an untapped market opportunity.

It is expected that development of a commercial product will be ready for UK
launch in May 2005, and the joint venture plans to expand distribution into the
USA and Japan thereafter.

In Europe, approximately 40% of all deaths can be attributed to circulatory
diseases, the driving force behind the $4bn global market for products that have
proven heart health benefits.

Provexis Limited was founded by ANGLE in 2000 using its established Progeny(R)
process as a joint venture with the Rowett Institute.  ANGLE retains a 32%
holding in Provexis.

The venture will be 55% owned by Provexis and product development will be funded
from Nutrinnovator's existing cash resources.

Commenting on the joint venture, Dr Stephen Franklin, CEO of Provexis said:

'We are delighted to announce the development of our Cardioflow product.

'Findings show that regular consumption of CardioFlow(R) make a significant
contribution to maintaining cardiovascular health, thereby reducing the risk of
a heart attack, stroke or Deep Vein Thrombosis (DVT).'

'The integration of CardioFlow(R) into a new branded beverage comes even earlier
than we had anticipated. The juice drink is just one example of the potential
opportunities open to Provexis, for the addition of CardioFlow through the
consumer food and drink market.'

Commenting on the joint venture, Andrew Newland, Chief Executive of ANGLE plc
said:

'The potential for ANGLE's venture company Provexis in the world cardiovascular
health market is significant and follows four years of hard work and investment.

'The development of this heart-healthy drink through the joint venture with
Nutrinnovator further demonstrates the value generation capability of ANGLE's
Progeny(R) process for commercialising intellectual property.'



For further information

ANGLE plc                                                     01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive

Buchanan Communications                                       020 7466 5000
Richard Darby, Suzanne Brocks



Notes to Editors

Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients.

ANGLE plc floated on the Alternative Investment Market of the London Stock
Exchange on 17 March 2004.



Nuttrinovator Holdings plc

Nutrinnovator develops and markets food and drink products of superior
nutritional quality, whilst retaining high quality taste, palatability and
consumer appeal.




                      This information is provided by RNS
            The company news service from the London Stock Exchange          KDKBFBKDQCB